台灣進入已開發國家，國內醫療費用支出大幅成長，本研究以羅氏大藥廠治療高血壓及心衰竭的乙型交感神經阻斷劑；DILATREND（beta-blocker）於台灣高血壓臨床指引（2010年版）發表後，於台灣地區的各級醫療院所使用乙型阻斷劑該類藥品影響之研究。近年來分量迴歸已廣泛運用在各學術領域，少有文獻運用於藥品市場研究上，本研究擬採用分量迴歸來探討台灣各區域及醫院層級，研究資料以台灣健康保險局乙型交感神經阻斷劑2011年健保資料庫的資料，藉由OLS及分量迴歸來探討，研究各層級醫療院所及不同區域上及使用該藥品的差異性。結果顯示，不同區域和不同層級的醫療院所使用者皆有差異性，較明顯於南區的低分位的地區醫療院所。皆比其他區域有差異性。在實務業務上的推廣該區短時間在地區醫療院所進行推廣，可以有看到顯著的改善。藉由該研究可以推廣至其他的藥品用於不同區域上或是高低分位的使用差異性，並協助各家公司針對不同的區域上推廣適合的行銷策略。

Taiwan could be definite as a developed country and the domestic medical costs grow aggressively. This research aims on the influence of the use of the beta-adrenergic blocker (β-blocker) in Taiwan medical institutions after Roche published theβ-blocker, DILATREND, which is the treatment for hypertension and heart failure in Taiwan hypertension clinical guidelines (2010 Edition). In recent years, quantile regression model has been widely used in the academic field, but is rarely applied in the drug market research. The quantile regression model and O LS are used in this research to discuss the diversity o f the β-blocker in different regions and different levels of medical institutions in Taiwan. The research data is obtained from the database of the β-blocker in Bureau of National Health Insurance in 2011. The result shows that the diversity exits in different regions and different levels of medical institutions. In the low quantile, there is more significant differentiation of the medical institutions in the south region than them in the other regions. The obvious improvement of business promotion of medical institutions is observed in above region, and could be spread for a short period of time. This study can be applied to other drugs adopted in different regions or high-low quantiles of medical institutions, and help companies develop optimal marketing strategies in different regions.